Clinical Trial Update: The Continuation of Erlotinib [Phase 2]

View source ↗

Summary

A Phase 2 trial continuation of Erlotinib for non-small cell lung cancer is noted, with no results or status details provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN